Clinical pearl: for invasive aspergillosis, the first move is a triazole, and the specific one is voriconazole, remembered as 'V for the Vessel-invading Aspergillus'.
Voriconazole earned its first-line spot after a controlled trial demonstrated better outcomes than amphotericin B deoxycholate. It works by inhibiting ergosterol biosynthesis, weakening the fungal membrane.
Sort the rest by role: liposomal amphotericin B is the principal alternative when voriconazole is contraindicated; caspofungin, an echinocandin acting on the cell wall, and posaconazole are reserved for salvage therapy or prophylaxis. That keeps voriconazole as the single best answer.